OHTUVAYRE (ensifentrine)
PHOSPHODIESTERASE-4 (PDE4) INHIBITORS · CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Merck Sharp & Dohme
Drug class
Phosphodiesterase-4 (PDE4) inhibitors
Phosphodiesterase-4 (PDE4) inhibitors are a class of targeted anti-inflammatory agents that selectively block the intracellular enzyme phosphodiesterase-4, preventing the degradation of cyclic adenosine monophosphate (cAMP). Read more about Phosphodiesterase-4 (PDE4) inhibitors
20 drugs in this class 18 manufacturers
Drugs in Phosphodiesterase-4 (PDE4) inhibitors
ROFLUMILAST
PHOSPHODIESTERASE-4 (PDE4) INHIBITORS · PREVENTION OF BRONCHOSPASM WITH CHRONIC BRONCHITIS
AVKARE
Filter & compare in the drug finder →
Opens the drug finder with Phosphodiesterase-4 (PDE4) inhibitors preselected. Add indication or manufacturer filters there.
Phosphodiesterase-4 (PDE4) inhibitors are a class of targeted anti-inflammatory agents that selectively block the intracellular enzyme phosphodiesterase-4, preventing the degradation of cyclic adenosine monophosphate (cAMP).
By elevating intracellular cAMP levels within immune and structural cells, these agents suppress downstream pro-inflammatory cytokines while promoting anti-inflammatory signaling cascades.
Available in oral, topical, and inhaled formulations, the class is primarily indicated for managing chronic inflammatory and autoimmune conditions across pulmonary and dermatological medicine, including chronic obstructive pulmonary disease (COPD), plaque psoriasis, psoriatic arthritis, and atopic dermatitis.
-
fda.gov
Phosphodiesterase-4 (PDE4) inhibitors are a class of targeted anti-inflammatory agents that selectively block the intracellular enzyme phosphodiesterase-4, preventing the degradation of cyclic adenosine monophosphate (cAMP) By elevating intracellular cAMP levels within immune and structural cells, these agents suppress downstream pro-inflammatory cytokines while promoting anti-inflammatory signaling cascades
-
nih.gov
Phosphodiesterase-4 (PDE4) inhibitors are a class of targeted anti-inflammatory agents that selectively block the intracellular enzyme phosphodiesterase-4, preventing the degradation of cyclic adenosine monophosphate (cAMP) Available in oral, topical, and inhaled formulations, the class is primarily indicated for managing chronic inflammatory and autoimmune conditions across pulmonary and dermatological medicine, including chronic obstructive pulmonary disease (COPD), plaque psoriasis, psoriatic...
-
fda.gov
By elevating intracellular cAMP levels within immune and structural cells, these agents suppress downstream pro-inflammatory cytokines while promoting anti-inflammatory signaling cascades
-
fda.gov
Available in oral, topical, and inhaled formulations, the class is primarily indicated for managing chronic inflammatory and autoimmune conditions across pulmonary and dermatological medicine, including chronic obstructive pulmonary disease (COPD), plaque psoriasis, psoriatic arthritis, and atopic dermatitis
-
nih.gov
Available in oral, topical, and inhaled formulations, the class is primarily indicated for managing chronic inflammatory and autoimmune conditions across pulmonary and dermatological medicine, including chronic obstructive pulmonary disease (COPD), plaque psoriasis, psoriatic arthritis, and atopic dermatitis
-
nih.gov
Available in oral, topical, and inhaled formulations, the class is primarily indicated for managing chronic inflammatory and autoimmune conditions across pulmonary and dermatological medicine, including chronic obstructive pulmonary disease (COPD), plaque psoriasis, psoriatic arthritis, and atopic dermatitis
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.